tirzepatide ema Tirzepatide EMA probes suicide risk with

A 2025 real-world cohort study on the risk of vestibular disorders with semaglutide reported that 15% of patients experienced dizziness after starting treatment, indicating this is not a rare, anecdotal complaint but a pattern clinicians should expect

Global Cancer Observatory: Cancer Over Time

Ask specifically: Does my plan cover semaglutide (Wegovy) for weight management? Get the answer in writing if possible

HCPCS modifiers RT and LT Appended to the CPT code to identify the right (RT) or left (LT) hip

Clinical trials show appetite hormones (GLP-1, PYY, GIP) return toward baseline within weeks of stopping medication, increasing hunger signals and food cravings significantly